Payment overview · 2025
General Payments
$2,519.61
95 reported records · 19 companies
Healthcare provider profile · identity verified
Vikram Gupta, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CLIFTON, NJ · NPI 1750538609
Verified facts
What the public records show
CMS Open Payments records show Vikram Gupta, M.D. received $2,519.61 in general payments during 2025 across 95 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Verquvo, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Soliqua 100-33 by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $651.41 | 25.9% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $278.53 | 11.1% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $213.69 | 8.5% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.00 | 7.6% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $190.09 | 7.5% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $185.91 | 7.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.83 | 5.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $132.55 | 5.3% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $128.47 | 5.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $105.48 | 4.2% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $89.06 | 3.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.83 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.91 | 1.4% | 2 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $30.53 | 1.2% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $23.77 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.84 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.06 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.86 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.79 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,519.61 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $278.53 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $244.96 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $231.28 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $228.74 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $192.00 | 10 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $185.91 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $180.12 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $153.55 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $152.37 | 9 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $128.47 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.83 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $89.06 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $86.50 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.77 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.24 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.47 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.83 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.90 | 2 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 360 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 254 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 68 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 31 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
360 | 112 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
254 | 65 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
31 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
254 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 926 | 343 |
| Amlodipine Besylate | Amlodipine Besylate | 691 | 271 |
| Losartan Potassium | Losartan Potassium | 595 | 232 |
| Metformin Hcl | Metformin Hcl | 452 | 181 |
| Metoprolol Succinate | Metoprolol Succinate | 371 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 119 |
| Farxiga | Dapagliflozin Propanediol | 360 | 112 |
| Diclofenac Sodium | Diclofenac Sodium | 345 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 145 |
| Jardiance | Empagliflozin | 254 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 85 |
| Gabapentin | Gabapentin | 191 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 53 |
| Glipizide Er | Glipizide | 175 | 68 |
| Ibandronate Sodium | Ibandronate Sodium | 175 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 67 |
| Omeprazole | Omeprazole | 147 | 55 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 143 | 42 |
| Ozempic | Semaglutide | 133 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 130 | 52 |
| Simvastatin | Simvastatin | 119 | 42 |
| Famotidine | Famotidine | 117 | 53 |
| Chlorthalidone | Chlorthalidone | 111 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 58 |
| Januvia | Sitagliptin Phosphate | 109 | 32 |
| Metformin Hcl Er | Metformin Hcl | 104 | 44 |
| Eliquis | Apixaban | 94 | 27 |
| Ammonium Lactate | Ammonium Lactate | 93 | 43 |
| Lisinopril | Lisinopril | 93 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 37 |
| Meloxicam | Meloxicam | 85 | 37 |
| Valsartan | Valsartan | 85 | 31 |
| Finasteride | Finasteride | 84 | 35 |
| Furosemide | Furosemide | 84 | 39 |
| Carvedilol | Carvedilol | 83 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 27 |
| Alendronate Sodium | Alendronate Sodium | 78 | 30 |
| Donepezil Hcl | Donepezil Hcl | 73 | 25 |
| Allopurinol | Allopurinol | 72 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 37 |
| Alcohol Pads | Alcohol Antiseptic Pads | 68 | 21 |
| Kerendia | Finerenone | 68 | 19 |
| Torsemide | Torsemide | 67 | 21 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 64 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 29 |
| Glimepiride | Glimepiride | 56 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 26 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 55 | 12 |
| Linzess | Linaclotide | 52 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 52 | 14 |
| Alprazolam | Alprazolam | 51 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 22 |
| Azithromycin | Azithromycin | 49 | 45 |
| Dapagliflozin | Dapagliflozin Propanediol | 48 | 36 |
| Montelukast Sodium | Montelukast Sodium | 48 | 18 |
| Naproxen | Naproxen | 47 | 27 |
| Vascepa | Icosapent Ethyl | 46 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | 16 |
| Memantine Hcl | Memantine Hcl | 45 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 41 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 20 |
| Lokelma | Sodium Zirconium Cyclosilicate | 43 | 13 |
| Sertraline Hcl | Sertraline Hcl | 42 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 42 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 20 |
| Myrbetriq | Mirabegron | 41 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 19 |
| Atenolol | Atenolol | 38 | 14 |
| Levofloxacin | Levofloxacin | 38 | 36 |
| Prednisone | Prednisone | 38 | 27 |
| Spironolactone | Spironolactone | 38 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 14 |
| Mirtazapine | Mirtazapine | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 25 |
| Potassium Chloride | Potassium Chloride | 30 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 14 |
| Hydrocortisone | Hydrocortisone | 25 | 18 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 16 |
| Fenofibrate | Fenofibrate | 22 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | 12 |
| Glipizide | Glipizide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Pregabalin | Pregabalin | 21 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Digoxin | Digoxin | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | 11 |
| Enulose | Lactulose | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,519.61 · 95 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, CHARTIS CATHETER, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FASENRA, GARDASIL 9, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, RHINAER STYLUS, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VERQUVO, VIVAER STYLUS, VOQUEZNA, XIFAXAN, ZAVZPRET, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error